Literature DB >> 8037890

Topical corticosteroids and unwanted local effects. Improving the benefit/risk ratio.

M Mori1, N Pimpinelli, B Giannotti.   

Abstract

The main goal of pharmacological research in the field of topical corticosteroids (TCs) is to dissociate efficacy and adverse effects as much as possible. The optimal use of TCs, i.e. the careful evaluation of the benefit/risk ratio, depends on: (i) the chemical structure of the TC; (ii) the type of vehicle; (iii) the mode of application; and (iv) the features of the skin to be treated. The recent availability of TCs characterised by a good dissociation between efficacy and adverse effects makes the classic and widely used classification system of TCs based upon potency out of date. Indeed, TCs with increasing potency have been characterised up to now, as a rule, by an increasing risk of adverse effects. Therefore, a classification system taking into major account the benefit/risk ratio seems particularly needed for clinical use in dermatology.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8037890     DOI: 10.2165/00002018-199410050-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  34 in total

1.  EXISTENCE OF RESERVOIR IN THE STRATUM CORNEUM. EXPERIMENTAL PROOF.

Authors:  C F VICKERS
Journal:  Arch Dermatol       Date:  1963-07

Review 2.  Current treatment guidelines for topical corticosteroids.

Authors:  B Giannotti
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Effects of topical corticosteroids on human dermis.

Authors:  R M Lavker; N M Schechter; G S Lazarus
Journal:  Br J Dermatol       Date:  1986-08       Impact factor: 9.302

4.  Flexible classification for the clinical potency of topical corticosteroid proprietaries.

Authors:  R M Fusaro
Journal:  Drug Intell Clin Pharm       Date:  1988-05

5.  Bioavailability of topical steroids.

Authors:  B W Barry
Journal:  Dermatologica       Date:  1976

6.  17-Heteroaroyl esters of corticosteroids. 2. 11 beta-Hydroxy series.

Authors:  E L Shapiro; M J Gentles; R L Tiberi; T L Popper; J Berkenkopf; B Lutsky; A S Watnick
Journal:  J Med Chem       Date:  1987-09       Impact factor: 7.446

7.  A separation of clinical from epidermal thinning effect in the topical glucocorticoid clobetasone butyrate.

Authors:  D V Stevanovic; L Wilson; C G Sparkes
Journal:  Br J Dermatol       Date:  1977-01       Impact factor: 9.302

8.  Improved delivery through biological membranes. 11. A redox chemical drug-delivery system and its use for brain-specific delivery of phenylethylamine.

Authors:  N Bodor; H H Farag
Journal:  J Med Chem       Date:  1983-03       Impact factor: 7.446

9.  Topical corticosteroids: clinical pharmacology and therapeutic use.

Authors:  J A Miller; D D Munro
Journal:  Drugs       Date:  1980-02       Impact factor: 9.546

10.  Systemic effects of local treatment with high doses of potent corticosteroids in psoriatics.

Authors:  J E Nilsson; L J Gip
Journal:  Acta Derm Venereol       Date:  1979       Impact factor: 4.437

View more
  3 in total

Review 1.  Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept.

Authors:  M Schäfer-Korting; M H Schmid; H C Korting
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

2.  Epidermal anti-Inflammatory properties of 5,11,14 20:3: effects on mouse ear edema, PGE2 levels in cultured keratinocytes, and PPAR activation.

Authors:  Alvin Berger; Irina Monnard; Markus Baur; Corinne Charbonnet; Irina Safonova; André Jomard
Journal:  Lipids Health Dis       Date:  2002-12-06       Impact factor: 3.876

Review 3.  Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders.

Authors:  A Prakash; P Benfield
Journal:  Drugs       Date:  1998-01       Impact factor: 11.431

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.